i
Hydroxyurea Use Among Medicaid Beneficiaries with Sickle Cell Disease in California and Georgia, 2006–2016
-
June 04, 2021
Details:
-
Corporate Authors:
-
Description:During 2006–2016, the use of hydroxyurea (HU) among Medicaid beneficiaries with sickle cell disease (SCD) who lived in California or Georgia increased. However, many beneficiaries with severe complications of SCD do not use HU.
HU was approved by the FDA in 1998 for the treatment of severe SCD in adults and in 2017 for the treatment of pediatric patients. It can decrease several complications of SCD, including severe acute pain episodes and acute chest syndrome, and may lead to fewer hospitalizations and improved survival.
CS 311531-A June 04, 2021
SCDC-data-brief-HU-h.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Genre:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: